277 related articles for article (PubMed ID: 24307762)
1. Vitreous inflammation associated with intravitreal anti-VEGF pharmacotherapy.
Agrawal S; Joshi M; Christoforidis JB
Mediators Inflamm; 2013; 2013():943409. PubMed ID: 24307762
[TBL] [Abstract][Full Text] [Related]
2. Incidence of presumed endophthalmitis after intravitreal injection performed in the operating room: a retrospective multicenter study.
Casparis H; Wolfensberger TJ; Becker M; Eich G; Graf N; Ambresin A; Mantel I; Michels S
Retina; 2014 Jan; 34(1):12-7. PubMed ID: 23945639
[TBL] [Abstract][Full Text] [Related]
3. Same-Day Bilateral Intravitreal Anti-Vascular Endothelial Growth Factor Injections: Experience of a Large Canadian Retina Center.
Juncal VR; Francisconi CLM; Altomare F; Chow DR; Giavedoni LR; Muni RH; Berger AR; Wong DT
Ophthalmologica; 2019; 242(1):1-7. PubMed ID: 30928983
[TBL] [Abstract][Full Text] [Related]
4. Complications of subspecialty ophthalmic care: endophthalmitis after intravitreal injections of anti-vascular endothelial growth factor medications.
Haddock LJ; Ramsey DJ; Young LH
Semin Ophthalmol; 2014; 29(5-6):257-62. PubMed ID: 25325851
[TBL] [Abstract][Full Text] [Related]
5. Local and systemic complications after intravitreal administration of anti-vascular endothelial growth factor agents in the treatment of different ocular diseases: a five-year retrospective study.
Nuzzi R; Tridico F
Semin Ophthalmol; 2015 Mar; 30(2):129-35. PubMed ID: 24171832
[TBL] [Abstract][Full Text] [Related]
6. Postinjection Endophthalmitis Rates and Characteristics Following Intravitreal Bevacizumab, Ranibizumab, and Aflibercept.
Rayess N; Rahimy E; Storey P; Shah CP; Wolfe JD; Chen E; DeCroos FC; Garg SJ; Hsu J
Am J Ophthalmol; 2016 May; 165():88-93. PubMed ID: 26944277
[TBL] [Abstract][Full Text] [Related]
7. Risk of Systemic Adverse Events after Intravitreal Bevacizumab, Ranibizumab, and Aflibercept in Routine Clinical Practice.
Maloney MH; Payne SR; Herrin J; Sangaralingham LR; Shah ND; Barkmeier AJ
Ophthalmology; 2021 Mar; 128(3):417-424. PubMed ID: 32781110
[TBL] [Abstract][Full Text] [Related]
8. Changes in Management Based on Vitreous Culture in Endophthalmitis After Intravitreal Anti-vascular Endothelial Growth Factor Injection.
Patel SN; Storey PP; Pancholy M; Obeid A; Wibbelsman TD; Levin H; Hsu J; Garg SJ; Dunn JP; Vander JF
Am J Ophthalmol; 2019 Nov; 207():224-231. PubMed ID: 31201794
[TBL] [Abstract][Full Text] [Related]
9. Endophthalmitis associated with intravitreal anti-vascular endothelial growth factor therapy injections in an office setting.
Pilli S; Kotsolis A; Spaide RF; Slakter J; Freund KB; Sorenson J; Klancnik J; Cooney M
Am J Ophthalmol; 2008 May; 145(5):879-82. PubMed ID: 18329624
[TBL] [Abstract][Full Text] [Related]
10. COMPARATIVE RISK OF ENDOPHTHALMITIS AFTER INTRAVITREAL INJECTION WITH BEVACIZUMAB, AFLIBERCEPT, AND RANIBIZUMAB.
Bavinger JC; Yu Y; VanderBeek BL
Retina; 2019 Oct; 39(10):2004-2011. PubMed ID: 30312260
[TBL] [Abstract][Full Text] [Related]
11. Association of Acute Endophthalmitis With Intravitreal Injections of Corticosteroids or Anti-Vascular Growth Factor Agents in a Nationwide Study in France.
Baudin F; Benzenine E; Mariet AS; Bron AM; Daien V; Korobelnik JF; Quantin C; Creuzot-Garcher C
JAMA Ophthalmol; 2018 Dec; 136(12):1352-1358. PubMed ID: 30242325
[TBL] [Abstract][Full Text] [Related]
12. Ocular complications after anti-vascular endothelial growth factor therapy in Medicare patients with age-related macular degeneration.
Day S; Acquah K; Mruthyunjaya P; Grossman DS; Lee PP; Sloan FA
Am J Ophthalmol; 2011 Aug; 152(2):266-72. PubMed ID: 21664593
[TBL] [Abstract][Full Text] [Related]
13. A systematic review of the adverse events of intravitreal anti-vascular endothelial growth factor injections.
van der Reis MI; La Heij EC; De Jong-Hesse Y; Ringens PJ; Hendrikse F; Schouten JS
Retina; 2011 Sep; 31(8):1449-69. PubMed ID: 21817960
[TBL] [Abstract][Full Text] [Related]
14. Therapies for macular edema associated with central retinal vein occlusion: a report by the American Academy of Ophthalmology.
Yeh S; Kim SJ; Ho AC; Schoenberger SD; Bakri SJ; Ehlers JP; Thorne JE
Ophthalmology; 2015 Apr; 122(4):769-78. PubMed ID: 25576994
[TBL] [Abstract][Full Text] [Related]
15. Systemic and ocular safety of intravitreal anti-VEGF therapies for ocular neovascular disease.
Tolentino M
Surv Ophthalmol; 2011; 56(2):95-113. PubMed ID: 21335144
[TBL] [Abstract][Full Text] [Related]
16. Endophthalmitis after anti-VEGF injections.
Klein KS; Walsh MK; Hassan TS; Halperin LS; Castellarin AA; Roth D; Driscoll S; Prenner JL
Ophthalmology; 2009 Jun; 116(6):1225.e1. PubMed ID: 19486799
[No Abstract] [Full Text] [Related]
17. Safety and efficacy of intravitreal anti-VEGF injections for age-related macular degeneration.
Jeganathan VS; Verma N
Curr Opin Ophthalmol; 2009 May; 20(3):223-5. PubMed ID: 19367163
[TBL] [Abstract][Full Text] [Related]
18. Safety of bilateral intravitreal injections delivered in a teaching institution.
Chao DL; Gregori NZ; Khandji J; Goldhardt R
Expert Opin Drug Deliv; 2014 Jul; 11(7):991-3. PubMed ID: 24815986
[TBL] [Abstract][Full Text] [Related]
19. Vitreomacular Interface after Anti-Vascular Endothelial Growth Factor Injections in Neovascular Age-Related Macular Degeneration.
Veloso CE; Kanadani TM; Pereira FB; Nehemy MB
Ophthalmology; 2015 Aug; 122(8):1569-72. PubMed ID: 26038338
[TBL] [Abstract][Full Text] [Related]
20. Endophthalmitis after intravitreal vascular [corrected] endothelial growth factor antagonists: a six-year experience at a university referral center.
Moshfeghi AA; Rosenfeld PJ; Flynn HW; Schwartz SG; Davis JL; Murray TG; Smiddy WE; Berrocal AM; Dubovy SR; Lee WH; Albini TA; Lalwani GA; Kovach JL; Puliafito CA
Retina; 2011 Apr; 31(4):662-8. PubMed ID: 21836400
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]